

1           **Out-of-Pocket Spending for Health Care Within 90 Days of COVID-19 Hospitalization**

2  
3           Kao-Ping Chua, MD, PhD<sup>a,b</sup>, Rena M. Conti, PhD<sup>c</sup>, Nora V. Becker, MD, PhD<sup>d</sup>

4  
5           **Affiliations:**

6           <sup>a</sup>Department of Pediatrics, Susan B. Meister Child Health Evaluation and Research Center,  
7           University of Michigan Medical School, Ann Arbor

8  
9           <sup>b</sup>Department of Health Management and Policy, University of Michigan School of Public Health,  
10           Ann Arbor

11  
12           <sup>c</sup>Department of Markets, Public Policy, And Law, Institute for Health System Innovation and  
13           Policy, Questrom School of Business, Boston University, Boston

14  
15           <sup>d</sup>Department of Internal Medicine, Division of General Medicine, University of Michigan  
16           Medical School, Ann Arbor

17  
18           **Address correspondence to:** Kao-Ping Chua, MD, PhD, 300 North Ingalls St, SPC 5456, Room  
19           6E18, Ann Arbor, Michigan 48109-5456. E-mail: [chuak@med.umich.edu](mailto:chuak@med.umich.edu). Phone: 734-615-  
20           8169

21  
22           **Conflicts of interest:** The authors have no conflicts of interest to disclose.

23  
24           **Financial disclosures:** none

25  
26           **Word count:** 1199

27  
28           **Date:** June 11, 2021

29

## ABSTRACT

30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58

**INTRODUCTION:** Millions of U.S. patients have been hospitalized for coronavirus disease 2019 (COVID-19). After discharge, these patients often have extensive health care needs, but out-of-pocket burden for this care is poorly described. Using national data, we assessed out-of-pocket spending during the 90 days after COVID-19 hospitalization among privately insured and Medicare Advantage patients.

**METHODS:** In May 2021, we conducted a cross-sectional analysis of the IQVIA PharMetrics<sup>®</sup> Plus for Academics Database, a national de-identified claims database. Among privately insured and Medicare Advantage patients hospitalized for COVID-19 between March-June 2020, we calculated mean out-of-pocket spending for care within 90 days of discharge. To contextualize results, we repeated analyses for patients hospitalized for bacterial pneumonia.

**RESULTS:** Among 1,465 COVID-19 patients included, 516 (35.2%) and 949 (64.8%) were covered by private insurance and Medicare Advantage plans. Among these patients, mean (SD) post-discharge out-of-pocket spending was \$534 (1,045) and \$680 (1,360); spending exceeded \$2,000 for 7.0% and 10.3%. Compared with patients with pneumonia, mean post-discharge out-of-pocket spending among COVID-19 patients was higher among the privately insured (\$534 vs \$445) and lower among Medicare Advantage patients (\$680 vs \$918).

**CONCLUSIONS:** Out-of-pocket spending for immediate post-discharge care can be substantial for many patients hospitalized for COVID-19. Among Medicare Advantage patients, post-discharge out-of-pocket spending was higher after pneumonia hospitalizations, potentially because insurer cost-sharing waivers fully covered the costs of COVID-19-related readmissions during the study period. As many insurers allowed such waivers to expire in 2021, it is important to repeat analyses among patients more recently hospitalized for COVID-19.

59 **INTRODUCTION**

60 Millions of U.S. patients have been hospitalized for coronavirus disease 2019 (COVID-  
61 19).<sup>1</sup> After discharge, these patients often have extensive health care needs.<sup>2-4</sup> However, out-of-  
62 pocket burden for this care has been poorly described. Addressing this gap in knowledge is  
63 crucial, as substantial out-of-pocket burden for post-discharge care might exacerbate other  
64 financial stresses experienced by patients hospitalized for COVID-19, such as loss of savings,  
65 income, and employment.<sup>4</sup>

66  
67 Using national data, we assessed out-of-pocket spending during the 90 days after  
68 COVID-19 hospitalization among privately insured and Medicare Advantage patients and  
69 determined which services accounted for the most out-of-pocket spending. Analyses can inform  
70 policy discussions and public discourse regarding the financial health of COVID-19 survivors.

71

72 **METHODS**

73 *Study sample.* In May 2021, we conducted a cross-sectional analysis of the IQVIA  
74 PharMetrics<sup>®</sup> Plus for Academics Database, which contains medical and pharmacy claims from  
75 de-identified patients in all U.S. states. Data included 7.7 million patients covered by fully-  
76 insured private plans and 1.0 million patients covered by Medicare Advantage plans in 2020.  
77 Claims through September 30, 2020 were available at the time of analysis. Because data were  
78 de-identified, the Institutional Review Board of the University of Michigan Medical School  
79 exempted analyses from human subjects review.

80

81           We identified hospitalizations for privately insured and Medicare Advantage patients that  
82    had a primary diagnosis of COVID-19 (ICD-10-CM diagnosis code U071) and that began and  
83    ended between March 1-June 30, 2020. We limited analyses to each patient’s first hospitalization  
84    during this period. We excluded patients without continuous medical and pharmacy coverage  
85    during the 90 days after discharge, patients whose plan was the secondary insurer, and patients  
86    with missing out-of-pocket spending data on any claim during the 90 days after discharge.

87  
88           *Measures.* We calculated mean out-of-pocket spending (sum of deductibles, co-  
89    insurance, and co-payments) across all claims during the 90 days after discharge. Additionally,  
90    we calculated mean out-of-pocket spending for 14 service categories: additional hospitalizations,  
91    nursing facility admissions, outpatient (e.g., office visits), emergency department visits,  
92    radiology, laboratory, diagnostic/therapeutic procedures (e.g., colonoscopy, surgery),  
93    physical/occupational/speech/respiratory therapy, home health/hospice, transportation, clinician-  
94    administered medications (e.g., infusions), durable medical equipment and supplies, pharmacy-  
95    dispensed prescriptions, and miscellaneous (see **Appendix** for details). For context, we repeated  
96    analyses among a comparison group of patients hospitalized for bacterial pneumonia. Patients in  
97    this group met similar inclusion and exclusion criterion and did not overlap with the main  
98    sample.

99  
100           *Statistical analyses.* Within payer types, we compared post-discharge out-of-pocket  
101    spending for COVID-19 and pneumonia patients using a one-part generalized linear model with  
102    a log link and Poisson variance function, chosen based on the modified Park test.<sup>5</sup> Models

103 adjusted for age group, sex, Census region of residence, and month of admission. Analyses used  
104 SAS 9.4, Stata 15.1 MP, and two-sided hypothesis tests with  $\alpha = 0.05$ .

105

## 106 **RESULTS**

107 Of 2,275 COVID-19 patients meeting inclusion criteria, 810 (35.8%) were excluded,  
108 leaving 1,465 patients in the analytic sample. **Table 1** displays sample characteristics. Overall,  
109 516 (35.2%) and 949 (64.8%) patients were covered by private insurance and Medicare  
110 Advantage plans.

111

112 Among privately insured patients, mean (SD) post-discharge out-of-pocket spending was  
113 \$534 (1,045). For 36 (7.0%) and 15 (2.9%) patients, this spending exceeded \$2,000 and \$4,000.

114 Service categories accounting for the most out-of-pocket spending were pharmacy-dispensed  
115 prescriptions (\$130; 24.4% of out-of-pocket spending) and hospitalizations (\$111; 20.8%).

116 Among Medicare Advantage patients, mean post-discharge out-of-pocket spending was \$680  
117 (1,360). For 98 (10.3%) and 34 (3.6%) patients, this spending exceeded \$2,000 and \$4,000.

118 Service categories accounting for the most out-of-pocket spending were hospitalizations (\$183;  
119 27.0%) and nursing facility admissions (\$126; 18.6%) (**Table 2**). Among privately insured and

120 Medicare Advantage patients, 43.5% and 40.3% of out-of-pocket spending for pharmacy-

121 dispensed prescriptions was for anticoagulants, diabetes drugs (e.g., insulin and sulfonylureas),

122 and bronchodilators. In both populations, these medication classes accounted for the 3 highest

123 shares of out-of-pocket spending for pharmacy-dispensed prescriptions.

124

125           **Table 1** displays characteristics of the 1,374 patients hospitalized for pneumonia included  
126 in analyses. Among the 245 privately insured pneumonia patients, mean (SD) post-discharge out-  
127 of-pocket spending was \$450 (924), compared with \$534 among COVID-19 patients (adjusted  
128 difference: -\$131, 95% CI: -\$135, -\$128). Among the 1,129 Medicare Advantage patients, mean  
129 (SD) post-discharge out-of-pocket spending was \$918 (1,263), compared with \$680 among  
130 COVID-19 patients (adjusted difference: \$291, 95% CI: \$288, \$294). Among 370 Medicare  
131 Advantage patients with additional hospitalizations after a pneumonia hospitalization, 306  
132 (82.7%) had out-of-pocket spending for the additional hospitalizations. Among 206 Medicare  
133 Advantage patients with additional hospitalizations after a COVID-19 hospitalization, 141  
134 (68.1%) had out-of-pocket spending for the additional hospitalizations.

135

## 136 **DISCUSSION**

137           During the 90 days after COVID-19 hospitalization, privately insured and Medicare  
138 Advantage patients paid an average of \$534 and \$680 for health care; 7.0% and 10.3% of  
139 patients paid more than \$2,000. For privately insured patients, prescriptions and additional  
140 hospitalizations accounted for the highest shares of out-of-pocket spending. For Medicare  
141 Advantage patients, additional hospitalizations and nursing facility admissions accounted for the  
142 highest shares.

143

144           For the privately insured, post-discharge out-of-pocket spending was higher among  
145 patients hospitalized for COVID-19 than among patients hospitalized for pneumonia. Perhaps  
146 surprisingly, the opposite was true for Medicare Advantage patients. A potential explanation is  
147 that some post-discharge care for COVID-19 patients, including readmissions for COVID-19,

148 were covered by insurer cost-sharing waivers for COVID-19 hospitalizations.<sup>6</sup> In support of this  
149 possibility, Medicare Advantage patients who were hospitalized for COVID-19 and subsequently  
150 had additional hospitalizations were less likely to have out-of-pocket spending for these  
151 additional hospitalizations compared with pneumonia patients. As many insurers allowed their  
152 cost-sharing waivers to expire in early 2021<sup>7</sup>, post-discharge out-of-pocket spending among  
153 patients hospitalized for COVID-19 could now be higher than among study patients.

154

155         The pneumonia comparison highlights that out-of-pocket spending after hospitalization  
156 discharge can be high for many conditions. Even if future studies demonstrate that long-term  
157 out-of-pocket spending after COVID-19 hospitalization is not especially great compared with  
158 other conditions, this would not detract from the fact that the absolute level of this spending can  
159 still be substantial for many COVID-19 patients. Moreover, given the high volume of U.S.  
160 hospitalizations for COVID-19 to date<sup>1</sup>, the number of patients with substantial out-of-pocket  
161 spending for post-discharge care may be large. Consequently, monitoring out-of-pocket spending  
162 and the financial health of these patients is a key clinical and policy priority.

163

164         This study has limitations. First, analyses only captured the immediate period after  
165 COVID-19 hospitalization. Second, the post-discharge period in this study occurred during the  
166 early stages of the pandemic, when utilization of health care services decreased sharply owing to  
167 social distancing measures and fears of contracting COVID-19.<sup>8</sup> Post-discharge utilization, and  
168 therefore out-of-pocket spending, might be higher now that utilization is approaching pre-  
169 pandemic levels. Third, this study required hospital discharge by June 30, 2020 because a 90-day  
170 post-discharge period was needed and claims were complete only through September 30, 2020 at

171 the time of analysis. While necessary, this decision excluded patients with prolonged  
172 hospitalizations who may require intensive post-discharge care. Consequently, analyses likely  
173 underestimate out-of-pocket burden among all COVID-19 survivors. Finally, patients may not be  
174 fully representative of the entire privately insured and Medicare Advantage population.

175

## 176 **CONCLUSIONS**

177 In this national cohort of 1,465 patients hospitalized for COVID-19 during March-June  
178 2020, out-of-pocket spending within 90 days of discharge exceeded \$2,000 for approximately 1  
179 in 14 privately insured patients and 1 in 10 Medicare Advantage patients. Future studies should  
180 repeat analyses among patients more recently hospitalized for COVID-19 using longer follow-up  
181 periods.



182 **ACKNOWLEDGEMENTS**

183 **Author Contributions:** Dr. Chua had full access to all of the data in the study and takes  
184 responsibility for the integrity of the data and the accuracy of the data analysis.

185

186 *Study concept and design:* Chua, Conti, Becker

187 *Acquisition of data:* Chua

188 *Analysis and interpretation of data:* Chua, Conti, Becker

189 *Drafting of the manuscript:* Chua

190 *Critical revision of the manuscript:* Chua, Conti, Becker

191 *Statistical analysis:* Chua

192 *Study supervision:* Becker

193

194 **Funding source:** Funding for purchasing IQVIA data was partially provided by the Susan B.  
195 Meister Child Health Evaluation and Research Center at the University of Michigan Medical  
196 School. Dr. Chua's effort is supported by a career development award from the National Institute  
197 on Drug Abuse (grant number 1K08DA048110-01). The funders played no role in the design and  
198 conduct of the study; collection, management, analysis, and interpretation of the data;  
199 preparation, review, or approval of the manuscript; and decision to submit the manuscript for  
200 publication

201

202 **Conflicts of interest:** The authors have no conflicts of interest to disclose.

203

204   **REFERENCES**

- 205   1.   Centers for Disease Control and Prevention. Covid Data Tracker. [Internet]. 2021;  
206       <https://covid.cdc.gov/covid-data-tracker/#new-hospital-admissions>. Accessed June 3,  
207       2021.
- 208   2.   Lavery AM, Preston LE, Ko JY, et al. Characteristics of Hospitalized Covid-19 Patients  
209       Discharged and Experiencing Same-Hospital Readmission - United States, March-August  
210       2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(45):1695-1699.
- 211   3.   Weerahandi H, Hochman KA, Simon E, et al. Post-Discharge Health Status and  
212       Symptoms in Patients with Severe Covid-19. *J Gen Intern Med.* 2021;36(3):738-745.
- 213   4.   Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty-Day Outcomes  
214       among Patients Hospitalized with Covid-19. *Ann Intern Med.* 2021;174(4):576-578.
- 215   5.   Buntin MB, Zaslavsky AM. Too Much Ado About Two-Part Models and  
216       Transformation? Comparing Methods of Modeling Medicare Expenditures. *Journal of*  
217       *Health Economics.* 2004;23:525-542.
- 218   6.   America's Health Insurance Plans. Health Insurance Providers Respond to Coronavirus  
219       (Covid-19). [Internet]. 2021; [https://www.ahip.org/health-insurance-providers-respond-](https://www.ahip.org/health-insurance-providers-respond-to-coronavirus-covid-19)  
220       [to-coronavirus-covid-19](https://www.ahip.org/health-insurance-providers-respond-to-coronavirus-covid-19). Accessed May 25, 2021.
- 221   7.   Appleby J. Time to Say Goodbye to Some Insurers' Waivers for Covid Treatment Fees.  
222       [Internet]. 2021; [https://khn.org/news/article/time-to-say-goodbye-to-some-insurers-](https://khn.org/news/article/time-to-say-goodbye-to-some-insurers-waivers-for-covid-treatment-fees/)  
223       [waivers-for-covid-treatment-fees/](https://khn.org/news/article/time-to-say-goodbye-to-some-insurers-waivers-for-covid-treatment-fees/). Accessed May 25, 2021.
- 224   8.   Cox C, Amin K, Kamal R. How Have Health Spending and Utilization Changed During  
225       the Coronavirus Pandemic? 2021; [https://www.healthsystemtracker.org/chart-](https://www.healthsystemtracker.org/chart-collection/how-have-healthcare-utilization-and-spending-changed-so-far-during-the-coronavirus-pandemic/#item-start)  
226       [collection/how-have-healthcare-utilization-and-spending-changed-so-far-during-the-](https://www.healthsystemtracker.org/chart-collection/how-have-healthcare-utilization-and-spending-changed-so-far-during-the-coronavirus-pandemic/#item-start)  
227       [coronavirus-pandemic/#item-start](https://www.healthsystemtracker.org/chart-collection/how-have-healthcare-utilization-and-spending-changed-so-far-during-the-coronavirus-pandemic/#item-start). Accessed June 9, 2021.

228

**Table 1.** Characteristics of patients hospitalized for COVID-19 and pneumonia between March-June 2020, IQVIA PharMetrics® Plus for Academics Database

	COVID-19 (n= 1,465) <sup>a</sup>		Pneumonia (n = 1,374) <sup>b</sup>	
	Private insurance	Medicare Advantage	Private insurance	Medicare Advantage
<b>Number of patients</b>	516	949	245	1,129
<b>Age in years</b>				
0-17	6 (1.2%)	0 (0.0%)	17 (6.9%)	0 (0.0%)
18-34	33 (6.4%)	4 (0.4%)	25 (10.2%)	0 (0.0%)
35-54	226 (43.8%)	44 (4.6%)	86 (35.1%)	67 (5.9%)
55-64	202 (39.1%)	102 (10.7%)	99 (40.4%)	168 (14.9%)
65-74	45 (8.7%)	319 (33.6%)	14 (5.7%)	379 (33.6%)
75-85	3 (0.6%)	319 (33.6%)	4 (1.6%)	350 (31.0%)
≥ 86	1 (0.2%)	161 (17.0%)	0 (0.0%)	165 (14.6%)
<b>Sex</b>				
Male	322 (62.4%)	411 (43.3%)	121 (49.4%)	532 (47.1%)
Female	194 (37.6%)	538 (56.7%)	124 (50.6%)	597 (52.9%)
<b>Region</b>				
Northeast	150 (29.1%)	467 (49.2%)	25 (10.2%)	146 (12.9%)
Midwest	122 (23.6%)	308 (32.5%)	56 (22.9%)	617 (54.7%)
South	165 (32.0%)	110 (11.6%)	113 (46.1%)	275 (24.4%)
West	76 (14.7%)	62 (6.5%)	51 (20.8%)	90 (8.0%)
<b>Admission month</b>				
March	85 (48.1%)	143 (54.7%)	117 (24.1%)	447 (23.1%)
April	248 (18.8%)	519 (20.7%)	59 (16.7%)	261 (21.8%)
May	97 (16.7%)	196 (9.6%)	41 (11.4%)	246 (15.5%)
June	86 (16.7%)	91 (9.6%)	28 (11.4%)	175 (15.5%)
<b>Mean length of stay (SD)</b>	7.9 (8.2)	8.9 (7.9)	4.2 (4.2)	4.6 (3.4)
<b>Any intensive care unit utilization<sup>a</sup></b>	239 (46.3%)	339 (35.7%)	86 (35.1%)	437 (38.7%)

<sup>a</sup>Among 2,275 patients with an initial hospitalization for COVID-19 between March 1-June 30, 2020, 747 were excluded because they lacked continuous enrollment during the 90 days after discharge, 54 because their insurance was not primary, and 8 because of missing data for out-of-pocket spending. We excluded 1 additional patient owing to the occurrence of a hospitalization that had not resulted in discharge by September 30, 2020 (raising the possibility that out-of-pocket spending for this hospitalization was not fully observed). In total, 810 patients were excluded, leaving 1,465 COVID-19 patients.

<sup>b</sup>We identified 1,810 patients who had a hospitalization with a primary diagnosis code for bacterial pneumonia (ICD-10-CM diagnosis code J13-J18) and no secondary diagnosis code for COVID-19 (U017) between March 1-June 30, 2020, and who were not in the sample of 1,465 COVID-19 patients. Of the 1,813 patients, 365 were excluded because they lacked continuous enrollment during the 90 days after discharge, 47 because their insurance was not primary, 22 because of missing data for out-of-pocket spending, and 2 because they had a hospitalization that had not resulted in discharge by September 30, 2020. In total, 436 patients were excluded, leaving 1,374 pneumonia patients.

<sup>c</sup>Defined as having at least one claim during the hospitalization with a revenue code for intensive care unit (0200-0209) or coronary care unit (0210-0219).

**Table 2.** Out-of-pocket spending for health care in the 90 days after COVID-19 hospitalization, IQVIA PharMetrics® Plus for Academics Database

Service category <sup>a</sup>	Private insurance (n = 516)					Medicare Advantage (n = 949)				
	No. patients with ≥1 claim (% patients in sample)	Mean (SD) OOP spending per patient in sample	% of all OOP spending	No. patients with OOP spending (% patients in sample)	Mean (SD) OOP spending among patients with OOP spending	No. patients with ≥1 claim (% patients in sample)	Mean (SD) OOP spending per patient in sample	% of all OOP spending	No. patients with OOP spending (% patients in sample)	Mean (SD) OOP spending among patients with OOP spending
Hospitalization	56 (10.9%)	\$111 (638)	20.8%	35 (6.8%)	\$1634 (1896)	206 (21.7%)	\$183 (824)	27.0%	141 (14.9%)	\$1235 (1815)
Nursing facility	2 (0.4%)	\$0 (12)	0.1%	1 (0.2%)	\$281 (NA)	221 (23.3%)	\$126 (698)	18.6%	128 (13.5%)	\$936 (1695)
Outpatient services	450 (87.2%)	\$44 (100)	8.2%	223 (43.2%)	\$101 (132)	797 (84.0%)	\$36 (57)	5.2%	497 (52.4%)	\$68 (64)
ED visits	56 (10.9%)	\$31 (190)	5.9%	25 (4.8%)	\$647 (597)	183 (19.3%)	\$13 (49)	1.9%	103 (10.9%)	\$121 (95)
Radiology tests	223 (43.2%)	\$65 (239)	12.2%	120 (23.3%)	\$280 (431)	404 (42.6%)	\$36 (166)	5.3%	241 (25.4%)	\$142 (30)
Laboratory tests	320 (62.0%)	\$41 (207)	7.8%	139 (26.9%)	\$154 (377)	632 (66.6%)	\$7 (20)	1.0%	282 (29.7%)	\$23 (3)
Procedures	188 (36.4%)	\$58 (300)	10.9%	100 (19.4%)	\$301 (628)	485 (51.1%)	\$97 (430)	14.2%	271 (28.6%)	\$338 (7)
PT, OT, ST, RT	37 (7.2%)	\$9 (75)	1.7%	16 (3.1%)	\$292 (323)	114 (12.0%)	\$9 (50)	1.3%	58 (6.1%)	\$141 (1)
Home health and hospice	76 (14.7%)	\$6 (72)	1.1%	10 (1.9%)	\$290 (456)	192 (20.2%)	\$3 (14)	0.4%	66 (7.0%)	\$38 (4)
Transportation	11 (2.1%)	\$4 (65)	0.8%	4 (0.8%)	\$526 (595)	162 (17.1%)	\$33 (186)	4.8%	98 (10.3%)	\$319 (49)
Administered medications <sup>b</sup>	98 (19.0%)	\$6 (62)	1.1%	38 (7.4%)	\$78 (216)	214 (22.6%)	\$26 (259)	3.8%	73 (7.7%)	\$332 (88)
DME and supplies	476 (92.2%)	\$12 (51)	2.3%	55 (10.7%)	\$114 (115)	906 (95.5%)	\$10 (61)	1.5%	179 (18.9%)	\$56 (13)
Pharmacy <sup>c</sup>	459 (89.0%)	\$130 (261)	24.4%	420 (81.4%)	\$160 (282)	837 (88.2%)	\$87 (212)	12.9%	649 (68.4%)	\$128 (24)
Miscellaneous	179 (34.7%)	\$15 (131)	2.8%	31 (6.0%)	\$253 (480)	381 (40.1%)	\$14 (118)	2.1%	66 (7.0%)	\$207 (40)
<b>Any service category</b>	<b>510 (98.8%)</b>	<b>\$534 (1045)</b>	<b>100.0%</b>	<b>453 (87.8%)</b>	<b>\$608 (1095)</b>	<b>939 (98.9%)</b>	<b>\$680 (1360)</b>	<b>100.0%</b>	<b>868 (91.5%)</b>	<b>\$743 (140)</b>

OOP – out-of-pocket; ED – emergency department; PT – physical therapy; OT – occupational therapy; ST – speech therapy; RT – respiratory therapy; DME – durable medical equipment; NA: not-applicable

<sup>a</sup>These service categories were based on the Agency for Healthcare Research and Quality Clinical Classification Software algorithm for procedures, v2020-1 (available at [https://www.hcup-us.ahrq.gov/toolsssoftware/ccs\\_svcsproc/ccssvcsproc.jsp](https://www.hcup-us.ahrq.gov/toolsssoftware/ccs_svcsproc/ccssvcsproc.jsp)). See Appendix for details.

<sup>b</sup>Administered medications refer to medications administered by clinicians, such as injections and infusions at visits

<sup>c</sup>Includes prescriptions dispensed at pharmacies